Cardiff Oncology, Inc. (NASDAQ: CRDF) had an eventful trading day, starting with a minor decline of 3.02% before rallying strongly by 33.71% in the afterhours.
On January 18, Cardiff Oncology Inc. (CRDF) announced new data from its lead clinical program in KRAS-mutated metastatic colorectal cancer. While the company was happy
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.